Drug intelligence / Profile preview

7B8-MMAE

Development stage: Preclinical
Lead developer: XYone Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**7B8-MMAE** is a preclinical MUC1-C-targeted antibody-drug conjugate developed by XYone Therapeutics. It consists of the 7B8 anti-MUC1-C extracellular-domain antibody conjugated to the microtubule-disrupting payload monomethyl auristatin E through a V-C-PAB linker. The ADC binds MUC1-C on tumor cells, is internalized, and delivers MMAE intracellularly to induce apoptotic cytotoxicity. Preclinical studies reported activity in pancreatic ductal adenocarcinoma and metastatic colorectal cancer models. ([ascopubs.org](https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e15025))

Other names: 7B8 + MMAE7B8 + monomethyl auristatin E

Targets

TUBB (Tubulin (alpha and beta subunits))MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on 7B8-MMAE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7B8-MMAE.

Explore the full profile